The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Open accessAbstract
SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
(1953) · PubMed · Cited by 942
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845 · cited 1×
“The commonly-used reference models include the highest single agent (HSA) (9), Bliss (10), Loewe (11) and Zero interaction potency (ZIP) model (12).”
MethodSelf-citationSynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530
Self-citationHolbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Jeselsohn, R., Bergholz, J. S., Pun, M., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 276
An automated fitting procedure and software for dose-response curves with multiphasic features
Di Veroli, G. Y., Fornari, C., Goldlust, I., Mills, G., Koh, S. B., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2015) · Scientific Reports · doi:10.1038/srep14701 · Cited by 196
Prediction of drug combination effects with a minimal set of experiments
Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, K., & Aittokallio, T. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0122-4 · Cited by 175
Self-citationPrediction of multidimensional drug dose responses based on measurements of drug pairs
Zimmer, A., Katzir, I., Dekel, E., Mayo, A., & Alon, U. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606301113 · Cited by 157
Efficient measurement and factorization of high-order drug interactions inMycobacterium tuberculosis
Cokol, M., Kuru, N., Bicak, E., Larkins‐Ford, J., & Aldridge, B. B. (2017) · Science Advances · doi:10.1126/sciadv.1701881 · Cited by 140
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
Vlot, A. H. C., Aniceto, N., Menden, M. P., Ulrich-Merzenich, G. S., & Bender, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.002 · Cited by 128
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Stathias, V., Jermakowicz, A. M., Maloof, M. E., Forlin, M., Walters, W. M., Suter, R. K., Durante, M. A., Williams, S. L., Harbour, J. W., Volmar, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07659-z · Cited by 106
Synergistic drug combination effectively blocks Ebola virus infection
Sun, W., He, S., Martínez‐Romero, C., Kouznetsova, J., Tawa, G. J., Xu, M., Shinn, P., Fisher, E. G., Long, Y., Motabar, O., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.017 · Cited by 99
Prevalence and patterns of higher-order drug interactions in Escherichia coli
Tekin, E., White, C., Kang, T. M., Singh, N. P., Cruz‐Loya, M., Damoiseaux, R. D., Savage, V. M., & Yeh, P. J. (2018) · npj Systems Biology and Applications · doi:10.1038/s41540-018-0069-9 · Cited by 97
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
Systematic discovery of drug interaction mechanisms
Chevereau, G., & Bollenbach, T. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156098 · Cited by 89
He, L., Tang, J. P., Andersson, E. I., Timonen, S., Koschmieder, S., Wennerberg, K., Mustjoki, S. M., & Aittokallio, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3644 · Cited by 79
Self-citationPrediction of ultra-high-order antibiotic combinations based on pairwise interactions
Katzir, I., Cokol, M., Aldridge, B. B., & Alon, U. S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006774 · Cited by 77
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Ianevski, A., Kononov, A., Timonen, S., Aittokallio, T. A., & Giri, A. K. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007604 · Cited by 72
Self-citationDasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Kivioja, J. L., Thanasopoulou, A., Kumar, A., Kontro, M., Yadav, B., Majumder, M. M., Javarappa, K. K., Eldfors, S., Schwaller, J., Porkka, K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0327-2 · Cited by 63
Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 56
Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment
Cokol, M., Li, C., & Chandrasekaran, S. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006677 · Cited by 48
Davies, G., Boeree, M. J., Hermann, D., & Höelscher, M. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002851 · Cited by 43
Amzallag, A., Ramaswamy, S., & Benes, C. H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2642-7 · Cited by 37
Weiss, A., Roux-Bourdieu, M. L., Zoetemelk, M., Ramzy, G. M., Rausch, M., Harry, D., Miljkovic‐Licina, M., Falamaki, K., Wehrle‐Haller, B., Meraldi, P., et al. (2019) · Cancers · doi:10.3390/cancers11101612 · Cited by 35
Adam, I., Ibrahim, Y., & Gasim, G. I. (2018) · Malaria Journal · doi:10.1186/s12936-018-2265-x · Cited by 33
Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer
Song, H., Zeng, J., Roychoudhury, S., Biswas, P., Mohapatra, B. C., Ray, S., Dowlatshahi, K., Wang, J., Band, V., Talmon, G. A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0600 · Cited by 22
Emergent Gene Expression Responses to Drug Combinations Predict Higher-Order Drug Interactions
Lukačišin, M., & Bollenbach, T. (2019) · Cell Systems · doi:10.1016/j.cels.2019.10.004 · Cited by 21
Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults
Properzi, M., Magro, P., Castelli, F., & Quirós-Roldán, E. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1544491 · Cited by 13
Vascellari, S., Valletta, E., Perra, D., Pinna, E., Serra, A., Isaia, F., Pani, A., & Pivetta, T. (2019) · RSC Advances · doi:10.1039/c8ra09652j · Cited by 13
Aghababazadeh, F. A., Lu, P., & Fridley, B. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-50936-0 · Cited by 10
Transitions in interaction landscapes of multidrug combinationsPreprint
Kang, T. M., Østman, B., Cruz‐Loya, M., Lozano-Huntelman, N. A., Damoiseaux, R. D., Savage, V. M., & Yeh, P. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/367664 · Cited by 1
Research works printed but not linked: 3
- Loewe, 1953, The problem of synergism and antagonism of combineddrugs, ArzneimiettelForschung, 3, 286
- Lakhtakia, 2015, A historical tale of two Lymphomas: part II: non-Hodgkin lymphoma, Sultan Qaboos Univ. Med. J., 15, e317, 10.18295/squmj.2015.15.03.003 · doi:10.18295/squmj.2015.15.03.003
- Gadagkar, 2015, Computational tools for fitting the Hill equation to dose–response curves, J. Pharmacol. Toxicol. Methods, 71, 68, 10.1016/j.vascn.2014.08.006 · DOI
Cited by
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
Ianevski, A., Giri, A. K., & Aittokallio, T. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac382 · Cited by 778
Self-citationZheng, S., Wang, W., Aldahdooh, J., Malyutina, A., Shadbahr, T., Tanoli, Z., Pessia, A., & Tang, J. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.004 · Cited by 733
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
White, K. M., Rosales, R., Yildiz, S., Kehrer, T., Miorin, L., Moreno, E., Jangra, S., Uccellini, M. B., Rathnasinghe, R., Coughlan, L., et al. (2021) · Science · doi:10.1126/science.abf4058 · Cited by 343
Lin, J.-F., Hu, P.-S., Wang, Y.-Y., Tan, Y.-T., Yu, K., Liao, K., Wu, Q.-N., Li, T., Meng, Q., Lin, J.-Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00889-0 · Cited by 330
Metadata
- Authors
- Ianevski, A., Giri, A. K., & Aittokallio, T.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-04
- Volume
- 48
- Issue
- W1
- Pages
- W488-W493
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W3014482292
- Cited by
- 873
- References
- 36
- FWCI
- 62.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Academy of Finland (292611, 310507, 313267, 326238)
- Cancer Society of Finland
- Sigrid Jusélius Foundation
- European Union's Horizon 2020 Research and Innovation Programme
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.